Hemophagocytic Lymphohistiocytosis/Macrophage-Activation Syndrome (HLH/MAS) Following Treatment with Tisagenlecleucel

Reyes Maria Martin-Rojas; Ignacio Gomez-Centurion; Rebeca Bailen; Mariana Bastos; Francisco Diaz-Crespo; Diego Carbonell; Rafael Correa-Rocha; Marjorie Pion; Cristina Muñoz; Milagros Sancho; Isabel Gomez-Fernandez; Gillen Oarbeascoa; Ana Perez-Corral; Carolina Martinez-Laperche; Javier Anguita; Ismael Buño; Javier Menarguez; Jose Luis Diez-Martin; Mi Kwon

doi:10.22541/au.162845155.51165342/v1

loading page

Hemophagocytic Lymphohistiocytosis/Macrophage-Activation Syndrome (HLH/MAS) Following Treatment with Tisagenlecleucel

Reyes Maria Martin-Rojas,
Ignacio Gomez-Centurion,
Rebeca Bailen,
Mariana Bastos,
Francisco Diaz-Crespo,
Diego Carbonell,
Rafael Correa-Rocha,
Marjorie Pion,
Cristina Muñoz,
Milagros Sancho,
Isabel Gomez-Fernandez,
Gillen Oarbeascoa,
Ana Perez-Corral,
Carolina Martinez-Laperche,
Javier Anguita,
Ismael Buño,
Javier Menarguez,
Jose Luis Diez-Martin,
Mi Kwon

Abstract

CAR-T cell related HLH/MAS is an unusual manifestation of severe cytokine release syndrome (CRS) with high mortality rates and a challenging diagnosis. The establishment of specific diagnosis criteria is essential, and the combination of several techniques for CAR-T cell follow-up, allows a more precise management of this complication.

28 Jul 2021Submitted to Clinical Case Reports

Show details

Hide details

29 Jul 2021Submission Checks Completed

29 Jul 2021Assigned to Editor

08 Aug 2021Reviewer(s) Assigned

09 Sep 2021Review(s) Completed, Editorial Evaluation Pending

10 Sep 2021Editorial Decision: Revise Minor

17 Oct 20211st Revision Received

19 Oct 2021Submission Checks Completed

19 Oct 2021Assigned to Editor

19 Oct 2021Review(s) Completed, Editorial Evaluation Pending

01 Dec 2021Editorial Decision: Accept

Jan 2022Published in Clinical Case Reports volume 10 issue 1. 10.1002/ccr3.5209

Abstract

Peer review status:Published